4D Molecular Therapeutics (NASDAQ:FDMT) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• 4D Molecular Therapeutics has been restated with a "sell (D-)" rating by Weiss Ratings, indicating potential concerns about the company's performance.
• The stock price objective from Roth Capital has been reduced from $44.00 to $38.00, while other firms like Royal Bank of Canada maintained an "outperform" rating with a price objective of $26.00.
• 4D Molecular Therapeutics shares rose 20.4% to $12.04, despite reported earnings per share of ($0.98), missing expectations by 10 cents.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on FDMT. Roth Capital decreased their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Royal Bank Of Canada restated an "outperform" rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Tuesday. Finally, Chardan Capital restated a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $29.50.

4D Molecular Therapeutics Trading Up 20.4%

Shares of NASDAQ FDMT traded up $2.04 during mid-day trading on Friday, hitting $12.04. The company had a trading volume of 1,604,843 shares, compared to its average volume of 841,905. The company has a market capitalization of $562.31 million, a PE ratio of -3.42 and a beta of 2.93. The firm has a 50-day simple moving average of $7.92 and a two-hundred day simple moving average of $5.35. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. Sell-side analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its stake in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock valued at $81,000 after buying an additional 2,284 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock worth $43,000 after purchasing an additional 2,674 shares during the period. Dynamic Technology Lab Private Ltd lifted its holdings in 4D Molecular Therapeutics by 35.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company's stock worth $61,000 after purchasing an additional 4,295 shares during the last quarter. American Century Companies Inc. lifted its holdings in 4D Molecular Therapeutics by 12.9% during the 1st quarter. American Century Companies Inc. now owns 43,784 shares of the company's stock worth $141,000 after purchasing an additional 4,999 shares during the last quarter. Finally, Proficio Capital Partners LLC lifted its holdings in 4D Molecular Therapeutics by 26.0% during the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company's stock worth $75,000 after purchasing an additional 5,195 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.